Integrated plasma and exosome long noncoding RNA profiling is promising for diagnosing non-small cell lung cancer
Author:
Wang Na12, Yao Cong3, Luo Changliang14, Liu Shaoping5, Wu Long6, Hu Weidong7, Zhang Qian1, Rong Yuan12, Yuan Chunhui8, Wang Fubing129
Affiliation:
1. Department of Laboratory Medicine , Zhongnan Hospital of Wuhan University , Wuhan , P.R. China 2. Center for Single-Cell Omics and Tumor Liquid Biopsy, Zhongnan Hospital of Wuhan University , Wuhan , P.R. China 3. Health Care Department , Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology , Wuhan , P.R. China 4. Department of Laboratory Medicine , The People’s Hospital of Guangxi Zhuang Autonomous Region , Nanning , P.R. China 5. Medical Science Research Center, Zhongnan Hospital of Wuhan University , Wuhan , P.R. China 6. Department of Oncology , Renmin Hospital of Wuhan University , Wuhan , P.R. China 7. Department of Thoracic Surgery , Zhongnan Hospital of Wuhan University , Wuhan , P.R. China 8. Department of Laboratory Medicine , Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology , Wuhan , P.R. China 9. Wuhan Research Center for Infectious Diseases and Cancer, Chinese Academy of Medical Sciences , Wuhan , P.R. China
Abstract
Abstract
Objectives
Non-small cell lung cancer (NSCLC) accounts for more than 80 % of all lung cancers, and its 5-year survival rate can be greatly improved by early diagnosis. However, early diagnosis remains elusive because of the lack of effective biomarkers. In this study, we aimed to develop an effective diagnostic model for NSCLC based on a combination of circulating biomarkers.
Methods
Tissue-deregulated long noncoding RNAs (lncRNAs) in NSCLC were identified in datasets retrieved from the Gene Expression Omnibus (GEO, n=727) and The Cancer Genome Atlas (TCGA, n=1,135) databases, and their differential expression was verified in paired local plasma and exosome samples from NSCLC patients. Subsequently, LASSO regression was used to screen for biomarkers in a large clinical population, and a logistic regression model was used to establish a multi-marker diagnostic model. The area under the receiver operating characteristic (ROC) curve (AUC), calibration plots, decision curve analysis (DCA), clinical impact curves, and integrated discrimination improvement (IDI) were used to evaluate the efficiency of the diagnostic model.
Results
Three lncRNAs-PGM5-AS1, SFTA1P, and CTA-384D8.35 were consistently expressed in online tissue datasets, plasma, and exosomes from local patients. LASSO regression identified nine variables (Plasma CTA-384D8.35, Plasma PGM5-AS1, Exosome CTA-384D8.35, Exosome PGM5-AS1, Exosome SFTA1P, Log10CEA, Log10CA125, SCC, and NSE) in clinical samples that were eventually included in the multi-marker diagnostic model. Logistic regression analysis revealed that Plasma CTA-384D8.35, exosome SFTA1P, Log10CEA, Exosome CTA-384D8.35, SCC, and NSE were independent risk factors for NSCLC (p<0.01), and their results were visualized using a nomogram to obtain personalized prediction outcomes. The constructed diagnostic model demonstrated good NSCLC prediction ability in both the training and validation sets (AUC=0.97).
Conclusions
In summary, the constructed circulating lncRNA-based diagnostic model has good NSCLC prediction ability in clinical samples and provides a potential diagnostic tool for NSCLC.
Funder
Creative Research Groups of Hubei Provincial Natural Science Foundation Zhongnan Hospital of Wuhan University Medical Science and Technology Innovation Platform Construction Support Project medical Sci-Tech innovation platform of Zhongnan Hospital Medical Top-talented youth development project of Hubei Province and the Health Commission of Hubei Province scientific research project
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,General Medicine
Reference48 articles.
1. Ganti, AK, Klein, AB, Cotarla, I, Seal, B, Chou, E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol 2021;7:1824–32. https://doi.org/10.1001/jamaoncol.2021.4932. 2. American Society of Clinical Oncology. Lung cancer – non-small cell – statistics: cancer. Net Editorial Board; 2022. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics [Accessed 8 Aug 2022]. 3. Duma, N, Santana-Davila, R, Molina, JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 2019;94:1623–40. https://doi.org/10.1016/j.mayocp.2019.01.013. 4. Ma, C, Hu, K, Ullah, I, Zheng, Q-K, Zhang, N, Sun, Z-G. Molecular mechanisms involving the sonic hedgehog pathway in lung cancer therapy: recent advances. Front Oncol 2022;12:729088. https://doi.org/10.3389/fonc.2022.729088. 5. Mendoza, TR, Kehl, KL, Bamidele, O, Williams, LA, Shi, Q, Cleeland, CS, et al.. Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study. Support Care Cancer 2019;27:3439–47. https://doi.org/10.1007/s00520-018-4632-0.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|